1. Bielory L.Allergic and immunologic disorders of the eye. Part I: immunology of the eye. J Allergy Clin Immunol. 2000; 106:805–16.
Article
2. Weeke ER.Epidemiology of hay fever and perennial allergic rhinitis. Monogr Allergy. 1987; 21:1–20.
3. Foster CS.Immunologic Disorders of the Conjunctiva. Cornea and Sclera. Principles and Practices of Ophthalmology: Section. 8:2nd ed.Philadelphia: WB Saunders Publishers;1999; 65:803–28.
4. Spangler DL, Bensch G, Berdy GJ.Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelas-tine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther. 2001; 23:1272–80.
5. Kidd M, McKenzie SH, Steven I. et al. Australian Ketotifen Study Group. Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. Br J Ophthalmol. 2003; 87:1206–11.
6. Abelson MB, Ferzola NJ, McWhirter CL, Crampton HJ.Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population. Pediatr Allergy Immunol. 2004; 15:551–7.
Article
7. Metcalfe DD, Baram D, Mekori YA.Mast cells. Physiol Rev. 1997; 77:1033–79.
Article
8. Kempuraj D, Saito H, Kaneko A. . Characterization of mast cell-committed progenitors present in human umbilical cord blood. Blood. 1999; 93:3338–46.
Article
9. Kempuraj D, Asadi S, Zhang B. . Mercury induces inflammatory mediator release from human mast cells. J Neuroinflammation. 2010; 7:20.
Article
10. Nakahata T, Toru H.Cytokines regulate development of human mast cells from hematopoietic progenitors. Int J Hematol. 2002; 75:350–6.
Article
11. Yamaguchi M, Azuma H, Fujihara M. . Generation of a consid-erable number of functional mast cells with a high basal level of FcepsilonRI expression from cord blood CD34+ cells by co-cultur-ing them with bone marrow stromal cell line under serum-free conditions. Scand J Immunol. 2007; 65:581–8.
12. Yanni JM, Miller ST, Gamache DA. . Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol. 1997; 79:541–5.
Article
13. Abelson MB.Evaluation of olopatadine, a new ophthalmic anti-allergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol. 1998; 81:211–8.
Article
14. Fernández M, Wong E, Oehling A.Retrospective study of keto-tifen protective action in different allergopathies. Allergol Immunopathol (Madr). 1987; 15:369–73.
15. Yanni JM, Stephens DJ, Miller ST. . The in vitro and in vivo oc-ular pharmacology of olopatadine (AL-4943A), an effective an-ti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996; 12:389–400.
Article
16. Schoch C.In vitro inhibition of human conjunctival mast-cell de-granulation by ketotifen. J Ocul Pharmacol Ther. 2003; 19:75–81.
Article